PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY

被引：0
|
作者：
Cella, D. [1 ]
Ritchie, E. [2 ]
Fabbiano, F. [3 ]
Pigneux, A. [4 ]
Kanda, Y. [5 ]
Ivanescu, C. [6 ]
Pandya, B. [7 ]
Shah, M., V [8 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Weill Cornell Med, New York, NY USA
[3] Azienda Osped Osped Riuniti Villa Sofia Cervello, Sicily, Italy
[4] Ctr Hosp Univ Bordeaux, Bordeaux, France
[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan
[6] IQVIA, Amsterdam, Netherlands
[7] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[8] Astellas Pharma US Inc, Northbrook, IL USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN485
引用
收藏
页码：S531 / S531
页数：1
相关论文
共 50 条
  • [11] GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S.
    Pardee, J. Lee T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    HAEMATOLOGICA, 2019, 104 : 2 - 2
  • [12] Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3-Mutated (FLT3mut) and FLT3-Wild Type (FLT3wt) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study
    Griffin, James D.
    Shah, Manasee V.
    Song, Yan
    Yang, Hongbo
    BLOOD, 2018, 132
  • [13] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [14] Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.
    Perl, Alexander E.
    Larson, Richard A.
    Podoltsev, Nikolai Alexandrovich
    Strickland, Stephen
    Wang, Eunice S.
    Schiller, Gary J.
    Martinelli, Giovanni
    Neubauer, Andreas
    Sierra, Jorge
    Montesinos, Pau
    Recher, Christian
    Yoon, Sung-Soo
    Hosono, Naoko
    Onozawa, Masahiro
    Chiba, Shigeru
    Kim, Hee-Je
    Hasabou, Nahla
    Lu, Qiaoyang
    Tiu, Ramon Velasquez
    Levis, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [15] Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial
    Perl, Alexander E.
    Larson, Richard A.
    Podoltsev, Nikolai A.
    Strickland, Stephen
    Wang, Eunice S.
    Atallah, Ehab
    Schiller, Gary J.
    Martinelli, Giovanni
    Neubauer, Andreas
    Sierra, Jorge
    Montesinos, Pau
    Recher, Christian
    Yoon, Sung-Soo
    Hosono, Naoko
    Onozawa, Masahiro
    Chiba, Shigeru
    Kim, Hee-Je
    Hasabou, Nahla
    Lu, Qiaoyang
    Tiu, Ramon
    Levis, Mark J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 6 - 7
  • [16] Y Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes
    Zeidan, Amer M.
    Gilligan, Adrienne M.
    Gautam, Santosh
    Grinblatt, David L.
    Elsouda, Dina
    Sullivan, Loretta
    Pandya, Bhavik J.
    BLOOD, 2020, 136
  • [17] Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia
    Pandya, Bhavik J.
    Qi, Cynthia Z.
    Garnham, Andy
    Yang, Hongbo
    Shah, Manasee, V
    Zeidan, Amer M.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (10): : 1469 - 1481
  • [18] Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes
    Ghorab, Ahmad
    Litzow, Mark
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun
    Murthy, Hemant
    Alkhateeb, Hasan
    Begna, Kebede
    Patnaik, Mrinal
    Foran, James
    Badar, Talha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S306 - S306
  • [19] Clinical Outcomes of Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Single-Center Retrospective Review
    Yohannan, Binoy
    Cervoni-Curet, Frances
    Sridhar, Arthi
    Yang, Wei
    Rios, Adan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S221 - S221
  • [20] Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Canaani, Jonathan
    Rea, Bryan
    Sargent, Rachel L.
    Qualtieri, Julianne N.
    Watt, Christopher D.
    Morrissette, Jennifer J. D.
    Carroll, Martin
    Perl, Alexander E.
    BLOOD ADVANCES, 2019, 3 (10) : 1581 - 1585
12345